Products - Bladder cancer | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
View all What we do
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 52 products

Date | Title

Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]
Product type:
Guidance
Programme:
Technology appraisal guidance
Expected publication date:
15 June 2022
Erdafitinib for treating unresectable or metastatic urothelial cancer with FGFR3 alterations after a PD-1 or PD-L1 inhibitor (TA1062)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
12 May 2025
Suspected cancer: recognition and referral (NG12)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
1 May 2025
Published:
23 June 2015
Memokath 051 Ureter stent for ureteric obstruction (MTG75)
Product type:
Guidance
Programme:
Medical technologies guidance
Published:
7 December 2022
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
10 August 2022
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) (TA797)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 June 2022
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 May 2022
Synergo for non-muscle-invasive bladder cancer (MTG61)
Product type:
Guidance
Programme:
Medical technologies guidance
Published:
30 November 2021
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 October 2021
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
28 April 2021
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) (TA674)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
17 February 2021
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (IPG656)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
24 July 2019
Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (IPG638)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
30 January 2019
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (IPG628)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
19 September 2018
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 July 2018
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 June 2018
Bladder cancer: diagnosis and management (NG2)
Product type:
Guidance
Programme:
NICE guideline
Published:
25 February 2015
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 January 2013
Laparoscopic cystectomy (IPG287)
Product type:
Guidance
Programme:
Interventional procedures guidance
Published:
25 February 2009
Improving outcomes in urological cancers (CSG2)
Product type:
Guidance
Programme:
Cancer service guideline
Published:
19 September 2002
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
4 October 2022
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
3 May 2022
URO17 for detecting bladder cancer (MIB250)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
4 February 2021
ADXBLADDER for detecting bladder cancer (MIB180)
Product type:
Advice
Programme:
Medtech innovation briefing
Published:
12 April 2019
Suspected cancer (QS124)
Product type:
Quality standard
Last updated:
5 December 2017
Published:
30 June 2016
Bladder cancer (QS106)
Product type:
Quality standard
Published:
17 December 2015
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
24 July 2025
Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 February 2026
Suspected Cancer
Status:
In development
Programme:
NICE guideline
Expected publication date:
13 March 2026
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Electrically-stimulated intravesical chemotherapy for non-muscle invasive bladder cancer
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Bladder EpiCheck for the detection of bladder cancer recurrence (MT706)
Status:
Topic selection
Programme:
Diagnostics guidance
Expected publication date:
TBC
MemoKath Stent Insertion
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [TSID11953]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
URO17 for testing suspected bladder cancer
Status:
Topic selection
Programme:
Diagnostics guidance
Expected publication date:
TBC
Signatera molecular residual disease assay (MT741)
Status:
Topic selection
Programme:
Medical technologies guidance
Expected publication date:
TBC
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer [TSID12021]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG [ID6454]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy [ID6515]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [TSID12146]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Nogapendekin alfa inbakicept with intravesical BCG for previously treated non-muscle-invasive bladder cancer unresponsive to BCG [ID12193]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC